Dr. Salles on Frontline Management of Follicular Lymphoma

Video

Gilles Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses frontline treatment management for patients with follicular lymphoma.

Gilles Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses frontline treatment management for patients with follicular lymphoma.

For patients who are asymptomatic, observation is usually the optimal way to start treatment, says Salles. While rituximab (Rituxan) is effective in most patients with follicular lymphoma, those who are asymptomatic showed little benefit from rituximab maintenance in clinical trials.

But, patients who are symptomatic or have a high tumor burden have responded well to rituximab maintenance. In this setting, it has been shown to improve progression-free survival, but not overall survival (OS). Although OS is not improved, this treatment option is still important to consider as it improves the day-to-day management of the disease, says Salles.

New agents such as obinutuzumab (Gazyva) and the combination of rituximab plus lenalidomide (Revlimid) are currently being investigated in this setting, as well.

Related Videos
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD
Sundar Jagannath, MBBS
Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center
Ashwin Kishtagari, MD